SCLX

Scilex Holding Company

$1.61

-7.47%
SectorHealthcareIndustryDrug Manufacturers - GeneralCountryUnited States

Scilex Holding Company focuses on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Its commercial products include ZTlido (lidocaine topical system) 1.8% (ZTlido), a prescription lidocaine topical product for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a ready-to-use oral solution for the acute treatment of migraine with or without aura in adults; and GLOPERBA, a liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults.

Source: Yahoo Finance
Q-Score29/ 100
Market Cap$11.3M
P/E—
Dividend Yield0.00%
52-Week Range—
Next Earnings—
Analysts—
Beta1.05
AI summary

Price & performance

1M-54.9%
3M-71.7%
YTD-77.5%
1Y-85.1%
52-week range—
Beta1.05
Full chart and returns against a benchmark

Q-Score

29/ 100

Quality against peers; 50 is the peer median.

Growth18
Risk32
Performance27
Valuation54
Profitability55
Leverage18
Sentiment—
Every score and metric

News sentiment

Open News

Latest results · FY 2025

Revenue$30.3M-46.5%
Net income-$374.1M
Net margin—
Historical fundamentals

Red flags in filings

3active red flags
Going-concern doubtApr 10, 2026
Late filing noticeMay 15, 2026
Auditor changeDec 6, 2024
Filings, findings and the timeline

Revenue exposure

Regions, segments, customers and suppliers

Valuation

SCLXIndustryP/E—38.98P/S0.366.74EV/EBITDA—40.57P/B—10.26PEG——
Dividend yield0.00%
Every valuation metric